VIVUS, Inc.  

(Public, NASDAQ:VVUS)   Watch this stock  
Find more results for VVUS
-0.030 (-5.19%)
Real-time:   3:34PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.53 - 0.57
52 week 0.53 - 1.41
Open 0.57
Vol / Avg. 628,262.00/640,389.00
Mkt cap 58.22M
P/E 1.64
Div/yield     -
EPS 0.33
Shares 105.95M
Beta 0.77
Inst. own 37%
Mar 6, 2018
Q4 2017 VIVUS Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 7, 2017
Q3 2017 VIVUS Inc Earnings Call - Webcast
Nov 7, 2017
Q3 2017 VIVUS Inc Earnings Release
Oct 27, 2017
VIVUS Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -39.45% 18.75%
Operating margin 15.97% 44.81%
EBITD margin - 45.68%
Return on average assets -8.75% 7.99%
Return on average equity -825.33% 419.86%
Employees 65 -
CDP Score - -


900 E Hamilton Ave Ste 550
CAMPBELL, CA 95008-0643
United States - Map
+1-650-9345200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Officers and directors

David York Norton Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Seth H. Z. Fischer Chief Executive Officer, Chief Commercial Officer, Director
Age: 61
Bio & Compensation  - Reuters
Mark K. Oki CPA Chief Financial Officer, Chief Accounting Officer
Age: 48
Bio & Compensation  - Reuters
John L. Slebir Esq. Senior Vice President - Business Development, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Santosh T. Varghese M.D. Chief Medical Officer
Age: 47
Bio & Compensation  - Reuters
Thomas B. King Independent Director
Age: 62
Bio & Compensation  - Reuters
Jorge Plutzky M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Eric W. Roberts Independent Director
Age: 53
Bio & Compensation  - Reuters
Herman Rosenman CPA Independent Director
Age: 70
Bio & Compensation  - Reuters
Allan L. Shaw Independent Director
Age: 53
Bio & Compensation  - Reuters